SCHEMBL20207077

SCHEMBL20207077

CC(=O)OCC1O[C@@H](OC(C)=O)C(NC(=O)c2ccccc2)C(OC(C)=O)[C@H]1OC(C)=O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.73
KMT2A Q03164 1/20 0.67
TSHR P16473 1/20 0.57
POLB P06746 2/20 0.55
ALDH1A1 P00352 2/20 0.55
TGM2 P21980 1/20 0.54
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
KDM4E B2RXH2 1/20 0.48
CA12 O43570 5/20 0.47
CA1 P00915 5/20 0.47
CA2 P00918 5/20 0.47
CA4 P22748 2/20 0.47
CA5A P35218 2/20 0.47
CA7 P43166 2/20 0.47
CA5B Q9Y2D0 2/20 0.47
CA9 Q16790 3/20 0.47
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26873221 1.00 LMNA (0.73) LMNAKMT2ATSHRPOLBALDH1A1
SCHEMBL7152557 1.00 LMNA (0.73) LMNAKMT2ATSHRPOLBALDH1A1
SCHEMBL20202239 1.00 LMNA (0.73) LMNAKMT2ATSHRPOLBALDH1A1
SCHEMBL3393349 1.00 LMNA (0.73) LMNAKMT2ATSHRPOLBALDH1A1
SCHEMBL7152558 1.00 LMNA (0.73) LMNAKMT2ATSHRPOLBALDH1A1
SCHEMBL20202226 1.00 LMNA (0.73) LMNAKMT2ATSHRPOLBALDH1A1
SCHEMBL17527987 1.00 LMNA (0.73) LMNAKMT2ATSHRPOLBALDH1A1
SCHEMBL17527862 1.00 LMNA (0.73) LMNAKMT2ATSHRPOLBALDH1A1
SCHEMBL20202228 1.00 LMNA (0.73) LMNAKMT2ATSHRPOLBALDH1A1
SCHEMBL25476273 0.96 LMNA (0.68) LMNAKMT2ATSHRPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148468-A1 USE OF UAP INHIBITORS TO INHIBIT FLUX THROUGH THE HEXOSAMINE BIOSYNTHETIC PATHWAY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148468-A1 USE OF UAP INHIBITORS TO INHIBIT FLUX THROUGH THE HEXOSAMINE BIOSYNTHETIC PATHWAY UGDH, UMPS, UGGT1 LMNA 3970/4885KMT2A 4131/4885TSHR 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.